论文部分内容阅读
背景与目的肺癌严重威胁人类生存健康,有效的肿瘤标志物可以辅助诊断、判断预后和指导治疗。本研究旨在检测非小细胞肺癌患者肿瘤组织和血浆中烯醇化酶1(alpha-enolase,ENO1)蛋白水平,初步探讨ENO1作为肺癌相关蛋白标志物的可能性。方法采用Western blot方法检测16例肺鳞癌患者的肿瘤组织及其配对正常肺组织中ENO1蛋白水平。采用双抗体夹心酶联免疫吸附分析(enzyme-linked immunosorbent assay,ELISA)测定42例健康体检者、34例肺部良性疾病患者和84例非小细胞肺癌患者三组人群血浆中ENO1蛋白水平。结果在87.5%(14/16)的肺鳞癌患者肿瘤组织中ENO1蛋白表达量高于其配对正常肺组织;非小细胞肺癌患者血浆中ENO1蛋白水平高于健康体检者(P=0.031)和肺部良性疾病者(P=0.019),且ENO1蛋白在肺腺癌患者血浆中的水平高于肺鳞癌患者(P=0.023)。结论非小细胞肺癌肿瘤组织和血浆中ENO1蛋白水平升高,提示ENO1可作为潜在的非小细胞肺癌相关血浆蛋白标志物。
Background and objective Lung cancer is a serious threat to human survival and health, effective tumor markers can help diagnose, determine the prognosis and guide treatment. The purpose of this study was to examine the levels of alpha-enolase (ENO1) in tumor tissue and plasma in patients with non-small cell lung cancer (NSCLC) and to explore the possibility of ENO1 as a lung cancer-associated protein marker. Methods Western blot was used to detect ENO1 protein levels in 16 patients with squamous cell carcinoma of lung and their matched normal lung tissues. The levels of plasma ENO1 protein in 42 healthy subjects, 34 patients with benign lung diseases and 84 patients with non-small cell lung cancer were measured by enzyme-linked immunosorbent assay (ELISA). Results ENO1 protein expression was higher in tumor tissues of 87.5% (14/16) of lung squamous cell carcinoma patients than in matched normal lung tissues; ENO1 protein in non-small cell lung cancer patients was significantly higher than that in healthy controls (P = 0.031) and Pulmonary benign disease (P = 0.019), and ENO1 protein levels in plasma of patients with lung adenocarcinoma were higher than those of squamous cell carcinoma (P = 0.023). Conclusions ENO1 protein levels in non-small cell lung cancer tissues and plasma are elevated, suggesting that ENO1 may serve as a potential plasma protein marker for non-small cell lung cancer.